308 related articles for article (PubMed ID: 2052148)
21. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
Frohna PA; Rothblat DS; Joyce JN; Schneider JS
Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin.
D'Amato RJ; Benham DF; Snyder SH
J Neurochem; 1987 Feb; 48(2):653-8. PubMed ID: 3491879
[TBL] [Abstract][Full Text] [Related]
23. Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures.
Schmidt DE; Ebert MH; Lynn JC; Whetsell WO
J Neural Transm (Vienna); 1997; 104(8-9):875-85. PubMed ID: 9451719
[TBL] [Abstract][Full Text] [Related]
24. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
Bradbury AJ; Costall B; Domeney AM; Testa B; Jenner PG; Marsden CD; Naylor RJ
Neurosci Lett; 1985 Oct; 61(1-2):121-6. PubMed ID: 2417166
[TBL] [Abstract][Full Text] [Related]
25. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.
Mochizuki H; Imai H; Endo K; Yokomizo K; Murata Y; Hattori N; Mizuno Y
Neurosci Lett; 1994 Feb; 168(1-2):251-3. PubMed ID: 8028787
[TBL] [Abstract][Full Text] [Related]
26. Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.
Quik M; Police S; He L; Di Monte DA; Langston JW
Neuroscience; 2000; 98(2):263-73. PubMed ID: 10854757
[TBL] [Abstract][Full Text] [Related]
27. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man.
Burns RS; Markey SP; Phillips JM; Chiueh CC
Can J Neurol Sci; 1984 Feb; 11(1 Suppl):166-8. PubMed ID: 6608980
[TBL] [Abstract][Full Text] [Related]
28. Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity.
Oeckl P; Ferger B
Neuroscience; 2016 Nov; 337():218-223. PubMed ID: 27651149
[TBL] [Abstract][Full Text] [Related]
29. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK
Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355
[TBL] [Abstract][Full Text] [Related]
31. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
[TBL] [Abstract][Full Text] [Related]
32. Neuromelanin: a role in MPTP-induced neurotoxicity.
D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
Life Sci; 1987 Feb; 40(8):705-12. PubMed ID: 2880274
[TBL] [Abstract][Full Text] [Related]
33. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--III. Reversal by embryonic nigral dopamine grafts.
Sirinathsinghji DJ; Dunnett SB; Northrop AJ; Morris BJ
Neuroscience; 1990; 37(3):757-66. PubMed ID: 2247221
[TBL] [Abstract][Full Text] [Related]
34. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
35. Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity.
Kuhlmann AC; Guilarte TR
Toxicol Sci; 1999 Mar; 48(1):107-16. PubMed ID: 10330690
[TBL] [Abstract][Full Text] [Related]
36. Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+.
Nakamura S; Vincent SR
Neurosci Lett; 1986 Apr; 65(3):321-5. PubMed ID: 3487052
[TBL] [Abstract][Full Text] [Related]
37. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
[TBL] [Abstract][Full Text] [Related]
38. Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse.
Perry TL; Yong VW; Jones K; Wall RA; Clavier RM; Foulks JG; Wright JM
Neurosci Lett; 1985 Aug; 58(3):321-6. PubMed ID: 3876525
[TBL] [Abstract][Full Text] [Related]
39. Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey.
Graham WC; Hill DR; Woodruff GN; Sambrook MA; Crossman AR
Neurosci Lett; 1991 Sep; 131(1):129-34. PubMed ID: 1791971
[TBL] [Abstract][Full Text] [Related]
40. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
Przedborski S; Kostic V; Jackson-Lewis V; Naini AB; Simonetti S; Fahn S; Carlson E; Epstein CJ; Cadet JL
J Neurosci; 1992 May; 12(5):1658-67. PubMed ID: 1578260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
